(IMAGE)

Goethe University Frankfurt

Caption

The thalidomide derivatives C5, C6 and C7 alter CRBN – the “labeling machine” – so that it can bind to BCL-2. In this way, the BCL-2 molecule is marked for degradation – a possible new strategy against cancer.

Credit

Dr. Xinlai Cheng, Goethe University Frankfurt

Usage Restrictions

To be used only when reporting on Goethe University Frankfurt. Indicate copyright: Dr. Xinlai Cheng, Goethe University Frankfurt

License

Original content

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.